Online inquiry

IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14586MR)

This product GTTS-WQ14586MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14586MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ394MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ264MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ9774MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ11427MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ11505MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ15590MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ11159MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ11022MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW